(Q39078119)

8 September 2017

VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia (English)

1 reference

8 September 2017

0 references

Xiaochuang Luo

1

1 reference

8 September 2017

Maoxiao Feng

2

1 reference

8 September 2017

Xuejiao Zhu

3

1 reference

8 September 2017

Yumin Li

4

1 reference

8 September 2017

Jia Fei

5

1 reference

8 September 2017

Yuan Zhang

6

1 reference

8 September 2017

1 November 2013

1 reference

8 September 2017

1 reference

8 September 2017

18

1 reference

8 September 2017

6

1 reference

8 September 2017

334-340

1 reference

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

8 September 2017

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Expanding the use of arsenic trioxide: leukemias and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Enhanced Bcr-Abl-specific antileukemic activity of arsenic trioxide (Trisenox) through glutathione-depletion in imatinib-resistant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Long-term efficacy and safety of all-trans retinoic acid/arsenic trioxide-based therapy in newly diagnosed acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Angiogenesis: a target in solid tumors, also in leukemia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Autocrine stimulation of VEGFR-2 activates human leukemic cell growth and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Prediction of VEGF mRNA antisense oligodeoxynucleotides by RNA structure software and their effects on HL60 and K562 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

VEGF(165) promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Inhibition of both paracrine and autocrine VEGF/ VEGFR-2 signaling pathways is essential to induce long-term remission of xenotransplanted human leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Chemoresistance in human ovarian cancer: the role of apoptotic regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Ethacrynic acid and a derivative enhance apoptosis in arsenic trioxide-treated myeloid leukemia and lymphoma cells: the role of glutathione S-transferase p1-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Inhibition of microRNA with antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2F1607845413Y.0000000083

10.1179/1607845413Y.0000000083

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference